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m103340 Rebound Following the Discontinuation ofHeperin is not Caused by Hyperactive Pistelets
P.Theroux, Z. Xiao, Y. Lu, M. Ghitescu. Montreal Heart ktstitufe, Montreal,
Quebac, Canada
The mechanisms for rebound following the discontinuation of heparin (Hep)
are not clear. In this study, we investigated in 6 pts with unstable angina
a potential role of platelet (Pi) activation by Hep persisting beyond its anti-
coagulation effect. Membrane expression of GPllb/llla, using antf-CD41-PE
detected by flowcytometry, and PI aggregation (Agg) in PRP was quantified
before and 4 and 24 hrs after the discontinuation of a 48-hour infusion of
Hep, in the basal state and foIlowing agonist stimulation with low ADP (0.31
MM)and TRAP concentrations (0.625 YM).
D-dimere increased by 31% following Hep discontinuation as plasma
levels decreased and aPTT normalized. PI counts increased by 15% and
anti-CD41-PE fluorescence decreased by 12%. Agg to ADP was reduced by
33% and to TRAP by 68%.
Heparin Post-heparin
6 hrs 24 hrs
aPIT sec 50+ 9 23& 2* 24&2*
Hepaiin, U/l 0.34* 0.1 0.02 * 0.02” O.0* 0.00”
D-dlmsrs, g/1 0.50+ 0.38 0.59+ 0.42” 0.73+0.43’
PI counts,10911 155 l4O 176+ 31* 182 + 26*
Anti-CD41, units 11,4 * 1.9 10.6+ 3.4 10.0+ 1.7*
Anti-CD41 + TRAP 17.4* 6.5 16.6+ 11.6 14.7+ 7*
AggADP, slope 36& 14 46&24 24& 14*
AggTRAP, slope 64* 45 24* 11* 21 * 10*
*P <0.05 ve Heparin
Cone/us/on: Platelets become quiescent following the discontinuation of
heparin, showing that they do not contribute to rebound and that the proag-
gregant effects of heparin are rapidly reversible.
gen levels than those without recurrent events. A baseline fibrinogen >300
m~dl was associated with increased risk (OR 1.61, 95Y. Cl 1.02, 2.52). No
association was obsewed in patients experiencing non-Q wave Ml (elevated
creatine kinase MB fraction). Although heightened thrombin activity (FPA),
thrombin generation (TAT, FI .2) and platelet activation (surface P-Selectin
expression) were obsewed in patients with unstable angina at baseline (com-
pared to healthy, age-matched controls) that persisted throughout the 96 h
study period, there was no correlation between fibrinogen and either throm-
bin or platelet activation at any time points. Wa conclude that fibrinogen, an
acute phase protein is a marker of coronary disease activity in patients with
unstable angina, but may not be directly prothrombotic.
\ 1033-43 I The EcarinClottingTirne butnottheaPITiea
Reliable Indicator for PEG-Hirudin Blood Levels in
Patients with Unstable Angina Pectoris
C.Bode B. Kohleri, G. Steg2, C. Parow3, K. RObsamen3. i Med. Clinic
///, I.hiveraityof Heidelberg, Gerrnarry,2 Cardio/ogie, Ffopita/Bichat Paris,
France, 3Knoll AG Ludwigshafen, Germany
The aPTT is commonly used for monitoring tha anticoagulant activity of
r-hirudin but exhibits large interindividual variability and reaches a plateau
value at higher concentrations so that even severe overdosage may not
be detected. In contrast, the ecarin clotting time (ECT) utilizing prothrombin
conversion by the snake venom constituent ecarin, is linearly correlated.
with hirudin’s specific antithrombin activity. Aim of the present study was to
evaluate the ECT (1) in vitro, in plasma from volunteers and unstable angina
(UA) patients and (2) in UA patients treated with PEG-H, a long acting hirudin
derivative.
Metfrock In a randomized open study 67 patients with UA were treated
with 3 dosages of PEG-Hover 3days. ECT,aPTTand PEG-H concentration’s
were assessed.
Results: In vitro, no differences in the alooe of concentration reaoonse
cuwes of UA-patients or volunteers were found (y = 0.076 x +53.6, r =
1033-41 Increased Thrombin Formation in de Novo but not 0.98). In patients, the ECT showed a close linear relationship with PEG-H
in DeetstbilizingUnstable Angina During concentrations from IWI to 3000 rig/ml whereas no correlation was found
Spontaneous Iachemic Epiaodes: Different between PEG-H concentration and aPTT:
Triggers of Iachemia? PEG-H Dose Correlationcoefficient[r) Corm. No, of
G. Quaranta, L.M. Biaeucci, A. Meo, G. Liuzzo, G. Caligiuri, A.G. Rebuzzi,
W. van de Greef, C. Monaco, C. Kluft, A. Maseri. Cardiology, Catholic
Univaraity Rome, Italx PG-TNO Leiden (NL), USA
To evaluate whether different clinical presentations of unstable angina (UA)
are associated to a different degree or pattern of activation of the hemostatic
and of the fibrinolytic system, we measured, during an episode of sponta-
neous rest ischemia, plasma levels of Thrombin-Anti Thrombin Ill (TAT)and
Plasmin-a2-Antiplasmin (PAP) complexes, as markers of activation of coag-
ulation and fibrirrolyais respectively, in two groups of pta: 7 with de novo UA
(Gl) and 7 with crescendo UA (G2). Blood samples were taken at the onaet
of ECG changes (all pts had ST segment depression) and pain (Omin.) and
after 5’, 15’ and 60 min. in order to assess the peak values of TAT and PAP
during the episode. Results: (median and range): TAT levels in GI were 1.8
~g/L (0.3-4.15) at O min. and increased to 17 @L (2.S-60) after 5 to 15
min. (p= 0.013), conversely in G2 TAT levels were 2.15 I.JVL(1.4-3.6) at O
min. and raiaed to 4 @L (2-43) after 5 to 15 min. (p = ns). No significant
differences in both groups were obsewed in PAP Ievele(Gl: 650 @L, range
492-956 at Omin. vs 670 pg/L, range 415-977 at peak; G2: 460 @L, range
274-955 at Omin. vs 502 j@L, range 304-1027 at peak) Conclusions: pts
with de novo UA have significantly enhanced thrombin (but not plasmin)
production during spontaneous ischemic episodes than pts with crescendo
UA. These data suggest that different mechanisms may be responsible for
acute ischemic episodes in pts with different modes of presentation of UA,
and explain different resfmnse to antithrombotic therapy in UA patients.
m’103342 Fibrinogen, An Acute Phase Protein Is Not aMarker of Thrombin- or Platelet-Mediated
Prothrombotic Potential in Unstable Angina
R.C. Beeker, C.P. Cannon, R.P.Tracy, E. Bovill, F. Spencer, M. Bums,
S.P. Ball for the TIMI Ill Investigators. Univereifyofkfaaeachusefts Mediea/
School, Worcestac MA, USA
Plasma fibrinogen is predictive of clinical events among patients with cardio-
vascular disease. Whether it directly contributes to intravascular thrombosis
or sewes as a marker for disease activity has been difficult to elucidate.
Fibrinogen was measured serially in 1,473 patients with unstable angina and
non-O-wave Ml. Patients with unstable angina experiencing in-hospital spon-
taneous ischemia (p = 0.004) and the combined unsatisfactory outcome of
death, Ml and spontaneous iachemia (p = 0.003) had higher baseline fibrino-
.,
m~kg + mgfkgh withPEG-H aPTT ECT samples
0.10 + 0.010 0.1581 0.6795 168
0.15 + 0.015 0.0733 0.6762 1S8
0.20 + 0.020 0.0733 0.8089 141
Cone/usiorrs:The ECT is a simple and reliable asaay for bedside mon-
itoring of PEG-H therapy. This test may increase safety and efficacy of
therapeutic regimens involving direct thrombin inhibitors.
=j HepariniaMoreEffective Than kIOgatran,aNOv.1
Low-Molecular Weight Thrombin Inhibitor in
Unstable Coronary Dieease
K. Anderaen, P.Erik::on, G. K~llstr6m, E. Alfvegren, M. Dellborg fortha
TRIM Study Group. Osfrs Univeraify Hospital, Gdteborg, Sweden
According to the thrombin hypothesis, therapy directed against thrombin
will reduce clinical events in unstable coronary syndromes. In a double-
blind randomized multicenter ~rial we evaluated the effeets of the novel
low molecular weight thrombin inhibitor inogatren against standard dose
heparin. The study drug was given as a 72 hour infusion starting within 24
hours of the last episode of chest pain in 324 patients. Ischemic events
were evaluated by continuous ST-segment monitoring for 24 houra with
computerized vectorcardiography.Clinical events at 7 days sewed as clinical
end points.
Results:
Inogatran Heparin P
(n= 245) (n= 79)
ST episodes,n (+ SD) 2 (4.5) 1 (2.8) <0.001
PatientswifhST episodes 3s% 22% <0,01
Deeth/AMl or refractoryangina (n =24) 9% 4% n,s.
DeathlAM1/refractowor
recurrentangina~n= 150) 50% 35% <0.05
Conclusion: Heparin treatment is superior to the thrombin inhibitor in
suppressing myocardial ischemia and clinieel end points at short term follow-
UP.
